60
Participants
Start Date
November 18, 2021
Primary Completion Date
February 29, 2028
Study Completion Date
February 29, 2028
Olezarsen
Olezarsen will be administered by SC injection.
CTSI Investigational Pharmacy, New York
Milstein Hospital, New York
IDS Central, Philadelphia
Hospital Universitario 12 de Octubre, Madrid
Excel Medical Clinical Trials, LLC, Boca Raton
Hospital Universitario Virgen del Rocío, Seville
Department of Pharmacy, Park Ridge
University of Kansas Medical Center (KUMC), Kansas City
Groupement Hospitalier Est- Pharmacie Secteur Essais Clinique, Bron
Via Sergio Pansini 5, Napoli
Metabolicke centrum MU, Bratislava
UOC di Farmacia AOUP PAOLO GIACCONE, Palermo
Diabetes/Lipid Management & Research Center, Huntington Beach
Hôpital Bicêtre, Le Kremlin-Bicêtre
Ecogene-21, Chicoutimi
Institute de Recherches Cliniques de Montreal, Montreal
Nathalie Saint-Pierre, Montreal
Clinique des Maladies Lipidiques de Quebec Inc., Québec
Pharmacie Hopital de la Conception, Marseille
Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome
Academisch Medisch Centrum Goederenontvangst Apotheek t.a.v. Kenniscentrum, Amsterdam
Oslo Hospital Pharmacy Rikshospitalet, Oslo
Hospital da Senhora da Oliveira Guimaraes, Creixomil
Dra Margarida Falcao Centro Hospitalar Lisboa Ocidental Hospital Egas Moniz, Lisbon
Hospital Clínic Barcelona C/ Villarroel, Barcelona
Apokteket AB, Malmo
Royal Manchester Children's Hospital, Manchester
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY